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College of Cardiology, March 13 to 17, 2010, Atlanta, GeorgiaFrederic S. Resnic, MD, MSc, FACC, and Akshay Desai, MD, MPH, FACCThe 59th Annual Scientific Sessions of the American Col-
lege of Cardiology (ACC), held March 13 to 17, 2010, in At-
lanta, Georgia, provided a forum for the initial release of
clinical trial data and a comprehensive review of many
topics of significant interest to cardiothoracic surgeons.
We provide a brief overview of the 5 most innovative and
important developments from the ACC scientific sessions.
1. The EVEREST II Trial: Randomized Comparison of
Catheter-based Treatment for Severe Mitral Regurgita-
tion Versus Surgical Repair or Replacement. The results
of the randomized trial of catheter-based treatment for se-
vere mitral regurgitation (MR) and traditional mitral
valve (MV) repair or replacement surgery, the EVEREST
II study, were reported at the ACC Scientific Sessions on
March 13, 2010, by Dr Ted Feldman. In this important
study, patients with 3þ and 4þ MR, as assessed by
a blinded core echocardiographic laboratory, were ran-
domly assigned in a 2:1 manner to receive the MitraClip
device (Abbott Laboratories, Abbott Park, IL) (n ¼ 184)
or open MV surgical repair or replacement (n ¼ 95) and
then followed clinically for 1 year.1 The groups were well
balanced for demographic and clinical features, although
there was a slight excess of congestive heart failure in the
clip group compared with the surgical group (90.8% vs
77.9%, P<.001). The majority of patients (86%) treated
in the surgical arm underwent MV repair, with excellent
clinical outcomes.
In the per-protocol analysis, major adverse events at 30
days, including death, myocardial infarction, reoperation
for mitral disease, transfusion requirement more than 2
units, stroke, renal failure, sepsis, and deep wound infec-
tion, occurred in 9.6% of the clip group versus 57% of the
control group (P< .001 for superiority of the clip treat-
ment). This outcome was driven primarily by a signifi-
cantly increased need for blood transfusion in the
surgical group. Clinical success rate at 12 months, de-
fined as freedom from death and reoperation for MV sur-
gery and MR greater than 2þgrade, was 72.4% in the clip
group versus 87.8% in the control group (P< .001 forFrom the Brigham and Women’s Hospital and Harvard Medical School, Boston,
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per-protocol analysis, 82% in the clip group achieved
2þor less MR versus 97% in the control group. Symptom
control was excellent in both treated populations (New
York Heart Association class I or II at follow-up was
98% in the clip group vs 88% in the surgical group).
The results were unchanged when an intention-to-treat
analytic framework was used. The echocardiographic
results at 12 months also demonstrated significant im-
provements in left ventricular volumes and dimensions
with either treatment (clip or surgery).2
These initial results of the EVEREST II trial are pro-
vocative and indicate that the percutaneous edge-to-
edge treatment for significant MR afforded by the Mitra-
Clip device may be an important therapeutic option for
selected patients given the demonstrated safety, effec-
tiveness, and clinical benefit. Long-term follow-up data
will be collected in these patients through 5 years of fol-
low-up, at which time the durability and long-term effi-
cacy of the procedure will be evaluated.
2. The Veterans Affairs Cooperative Trial CSP-474 of
Radial Artery versus Saphenous Venous Grafting in Cor-
onary Artery Bypass Surgery. The optimal choice of
bypass conduit type beyond the routine use of the left in-
ternal thoracic artery graft during coronary artery bypass
grafting (CABG) has been controversial. Therefore, the
relative advantage of routine use of the radial artery
(RA) as a conduit during CABG was evaluated in the
Veterans Affairs cooperative study of the radial artery
versus saphenous venous grafting in coronary bypass
surgery. In this study performed at 11 VA cardiac surgi-
cal centers, Dr Steven Goldman presented the 1-year an-
giographic patency of RA conduits (n ¼ 366) compared
with the patency of saphenous vein (SV) grafts (n ¼
367). At 1 week, routine angiography demonstrated a pa-
tency rate of 99% for the RA grafts and 97% for the SV
grafts. At 1 year, both conduit types achieved an angio-
graphic patency rate of 89%. Secondary analyses demon-
strated a lower rate of SV patency if endoscopic
harvesting was used compared with open harvesting
techniques (12-month patency rates: 78% vs 91%, P<
.001). In addition, the RA grafts were more likely than
SV grafts to fail because of diffuse disease at 1 year (ie,
‘‘string sign’’ failure; 8% vs 1.0%, P< .001). The target
of the graft was not predictive of patency for the SV or
RA graft. Although on-pump procedures were associated
with higher patency rates for SV grafts compared with
off-pump bypass surgeries (90% vs 78%, P<.001), thererdiovascular Surgery c Volume 140, Number 1 257
Meeting Proceedings Resnic and Desaiwere no differences in the patency rates of RA grafts
stratified by on- or off-pump procedures.3
This Veterans Affairs cooperative study demonstrated
identical 12-month graft patency rates for RA versus
SV grafts during elective CABG. Additional angio-
graphic follow-up to 5 years is planned for patients
treated during this study, which should help to answer
whether longer-term patency rates remain similar be-
tween the 2 conduit types.
3. Additional Surgical Treatment of Ischemic Heart Failure
Trial Data Find No Subset of Patients Who Benefit from
Surgical Ventricular Reconstruction over Coronary
Artery Bypass Grafting Alone. The primary results for
‘‘hypothesis 1’’ of the Surgical Treatment of Ischemic
Heart Failure (STICH) trial revealed that among patients
with left ventricular ejection fraction of 35% or less, cor-
onary artery disease amenable to CABG, and predomi-
nant anterior left ventricular dysfunction amenable to
surgical ventricular reconstruction (SVR), the combina-
tion of SVR and CABG resulted in significant reduction
in left ventricular volumes but no improvement in anginal
symptoms, exercise tolerance, or the composite of death
or hospitalization for cardiovascular causes relative to
CABG alone.4
New subgroup analyses from STICH presented at
ACC 2010 shed additional light on this topic. Dr Robert
Michler presented data on the subgroup of 595 STICH
subjects with accurate measurements of preoperative
and 4-month postoperative end-systolic volume index
(ESVI). Among this subset (which had lower overall
mortality than the STICH population as a whole), no
group of patients deriving benefit from SVR could be
identified on the basis of segregation by preoperative
ESVI or achieved reduction in ESVI. As for the larger
trial, the achieved reduction in ESVI was greater in pa-
tients receiving CABGþ SVR versus CABG alone. Of
note, however, CABG alone was associated with
a mean 15% reduction in ESVI, with more than 20%
of patients achieving a reduction of more than 30%. Rel-
ative to CABG alone, a nonsignificant trend toward en-
hanced mortality was seen with combined SVR þ
CABG for patients with preoperative ESVI greater
than 90 mL/m2. Despite a trend favoring the addition
of SVR among those with an ESVI of 90 mL/m2 or
less, no statistically significant advantage over CABG
alone could be identified. These results were not altered
by confining the analysis to those with large achieved
postoperative reductions in ESVI.5
Overall, these data, which complement previous sub-
group analyses of global and regional left ventricular
function from STICH arriving at similar conclusions,
suggest that there is no definable subgroup of patients
with ischemic cardiomyopathy who clearly benefit258 The Journal of Thoracic and Cardiovascular Surgfrom the addition of SVR to CABG alone. Results
from hypothesis 1 of the STICH trial, investigating the
benefits of CABG relative to optimal medical therapy
in patients with coronary artery disease and left ventric-
ular dysfunction, are expected in 2011.
4. Ticagrelor versus Clopidogrel in Patients with Acute
Coronary Syndromes Undergoing Coronary Artery By-
pass Surgery—Platelet Inhibition and Patient Outcomes
Subanalysis. Although current guidelines support the
use of clopidogrel as an adjunct to aspirin therapy in pa-
tients with acute coronary syndromes, recent data high-
light that clopidogrel efficacy may be limited in
practice by substantial variability in platelet inhibition,
increased rates of bleeding (particularly after CABG),
and a higher risk of stent thrombosis and myocardial in-
farction in nonresponders.6 Ticagrelor is a novel, revers-
ible, oral antagonist of the adenosine diphosphate
receptor P2Y12 that provides faster, greater, and more
consistent P2Y12 inhibition than clopidogrel.7 The pri-
mary results of the Platelet Inhibition and Patient Out-
comes (PLATO) study, initially reported in 2009,8
revealed that in patients presenting with an acute coro-
nary syndrome, randomization to treatment with ticagre-
lor (180 mg loading dose, 90 mg twice daily thereafter)
versus clopidogrel (300–600 mg loading dose, 75 mg
daily thereafter) was associated with a statistically signif-
icant reduction in the rate of the composite end point of
death from vascular causes, myocardial infarction, or
stroke (9.8% vs 11.4%; hazard ratio [HR] 0.84; 95% con-
fidence interval [CI], 0.77–0.92; P< .001). Remarkably,
the benefit of ticagrelor over clopidogrel was not associ-
ated with an increase in the rate of major bleeding (11.6%
for ticagrelor vs 11.2% for clopidogrel, P ¼ .43).
At the ACC 2010 Scientific Sessions, Dr Claes Held
and colleagues presented additional data regarding out-
comes in the subgroup of 1260 patients randomized in
PLATOwho subsequently underwent CABGwith cessa-
tion of study drug within 7 days of surgery. In this prespe-
cified, but retrospective subgroup analysis, no difference
was seen between ticagrelor and clopidogrel with regard
to the primary composite PLATO outcome, the rates of
myocardial infarction, or the rates of stroke. However,
there was a striking, statistically significant 50% reduc-
tion in both all-cause (4.6% vs 9.2%, HR 0.49, P ¼
.002) and cardiovascular (4.0% vs 7.5%, HR 0.52, P ¼
.009) mortality in the ticagrelor-treated patients.9 Be-
cause no difference was seen between the 2 therapies
with regard to the rates of post-CABG bleeding, myocar-
dial infarction, or stroke, the mechanism of this substan-
tial mortality reduction remains unclear. Overall,
however, the promise of greater mortality reduction with-
out an incremental risk of bleeding around the time of
CABG heightens interest in ticagrelor as an alternativeery c July 2010
Resnic and Desai Meeting Proceedingsto clopidogrel in the management of patients with acute
coronary syndromes.
5. Five-Year Outcomes of the MAIN-COMPARE Registry
of Left Main Coronary Artery Revascularization with
Coronary Stenting versus Coronary Artery Bypass Graft-
ing. Dr Seung-Yung Park reported the 5-year outcomes
of the largest prospective registry of unprotected percuta-
neous coronary intervention versus CABG. Between Jan-
uary 2000 and June 2006, The Revascularization for
Unprotected Left MAIN Coronary Artery Stenosis:
COMparison of Percutaneous Coronary Angioplasty ver-
sus Surgical REvascularization fromMulti-Center Regis-
try (MAIN-COMPARE) collected detailed clinical and
angiographic information on 1106 patients treated with
coronary stenting compared with 1138 patients treated
with CABG. Patients were followed for 5 years after their
index procedure and evaluated for survival, Q-wave
myocardial infarction, stroke, and target vessel revascu-
larization using a propensity-matched algorithm. Before
matching, the patients who received percutaneous coro-
nary intervention were younger; less likely to have diabe-
tes, hyperlidemia, or renal insufficiency; less likely to be
active smokers; and more likely to have had prior coro-
nary interventional procedures.10 After the propensity
match, 542 pairs of well-matched patients, without re-
maining baseline clinical or angiographic differences,
were analyzed. At 3 years, there were no differences in
survival or subsequent myocardial infarction between
the treatment groups, although the stent group had
a higher rate of repeat revascularization than the CABG
group (12.6% vs 2.6%, P< .001).11 At a median of 5.2
years of follow-up, the clinical results seen at 3 years
were sustained. Although the rate of target vessel revas-
cularization was significantly higher in the stent group
(HR, 5.11; 95% CI, 3.52–7.42; P< .001), the risk of
death for the stent group was not significantly different
than that for the CABG group (HR 1.13; 95% CI,
0.88–1.44; P ¼ .35). The combined risk of death,
Q-wave myocardial infarction, and stroke (HR 1.07;
95% CI, 0.84–1.37; P¼ .59) was similar for both groups.
Stent type (bare metal or drug eluting) did not signifi-
cantly change these results. There was, however, a non-The Journal of Thoracic and Casignificant trend toward an increase in the absolute
mortality rate in the latter follow-up period (years 3–5)
in the stent group compared with the CABG group.10
The 5-year MAIN-COMPARE results are consistent
with the 1-year results of the SYNTAX trial, a prospective
trial of 1800 patients with either left main or 3-vessel cor-
onary artery disease undergoing revascularization who
were randomized to drug-eluting stent treatment or
CABG. The late separation of the mortality curves seen
in the MAIN-COMPARE study warrant continued study
through long-term follow-up of registry and randomized
trial left main revascularization cohorts.References
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